Nicotinic acetylcholine receptor peptide antagonist conotoxin compositions and related methods
The present invention relates to novel peptide antagonists that inhibit binding of acetylcholine to the active site of the muscle-type nicotinic acetylcholine receptor. The peptide antagonists of the invention are useful in cosmetic compositions that prevent or improve the appearance of skin wrinkles and related skin conditions. The invention further relates to cosmetic and pharmaceutical compositions comprising a peptide antagonist of the invention, and methods for their use.
1. A muscle-type nicotinic acetylcholine receptor peptide antagonist comprising an amino acid sequence:
Xaa3 - Xaa4 - Xaa5 - Xaa6 - Xaa7 - Xaa8 - Xaa9 -
Xaa10 - Xaa11 - Xaa12 - Xaa13 - Xaa14
wherein:
Xaa3 and Xaa8 form a linkage Xaa3-Xaa8;
Xaa4 and Xaa14 form a linkage Xaa4-Xaa14;
Xaa5 is selected from: Asn, Asp, Gln, Glu, Arg, His and Lys;
Xaa6 is selected from: Pro and hydroxyproline;
Xaa7 is selected from: Ala, Gly, Val, Leu, and Ile;
Xaa9 is selected from: Ala, Gly, Val, Leu, and Ile;
Xaa10 is selected from: His and Lys;
Xaa11 is selected from: Asp, Gln, Glu, Arg, His, and Lys;
Xaa12 is selected from: Trp and Tyr;
Xaa13 is selected from: Cys, Met, Sec, Ser, Thr, Arg, His, and Lys;
wherein Xaa3 and Xaa14 are terminal amino acids.
2. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 1 ,
wherein:
the Xaa3-Xaa8 linkage is selected from: a Cys-Cys linkage, a Sec-Sec linkage, a cystathionine linkage, a lactam bridge, a thioether linkage, and a dicarba linkage;
the Xaa4-Xaa14 linkage is selected from: a Cys-Cys linkage, a Sec-Sec linkage, a cystathionine linkage, a lactam bridge, a thioether linkage, and a dicarba linkage;
Xaa5 is selected from: Asn, Asp, Gln, Glu, and His;
Xaa6 is selected from: Pro and hydroxyproline;
Xaa7 is selected from: Ala, Gly, Val, Leu, and Ile;
Xaa9 is selected from: Ala, Gly, Val, Leu, and Ile;
Xaa10 is selected from: His and Lys;
Xaa11 is selected from: Asp, Gln, Glu, Arg, His, and Lys;
Xaa12 is selected from: Trp and Tyr; and
Xaa13 is selected from: Cys, Met, Sec, Ser, and Thr.
3. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 1 ,
wherein:
the Xaa3-Xaa8 linkage is selected from: a Cys-Cys linkage, a Sec-Sec linkage, a cystathionine linkage, a lactam bridge, a thioether linkage, and a dicarba linkage;
the Xaa4-Xaa14 linkage is selected from: a Cys-Cys linkage, a Sec-Sec linkage, a cystathionine linkage, a lactam bridge, a thioether linkage, and a dicarba linkage;
Xaa5 is selected from: Asn, Asp, Gln, Glu, Arg, His and Lys;
Xaa6 is selected from: Pro and hydroxyproline;
Xaa7 is selected from: Ala, Gly, Val, Leu, and Ile
Xaa9 is selected from: Ala, Gly, Val, Leu, and Ile;
Xaa10 is selected from: His and Lys;
Xaa11 is selected from: Arg, His, and Lys;
Xaa12 is selected from: Trp and Tyr; and
Xaa13 is selected from: Cys, Met, Sec, Ser, and Thr.
4. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 1 ,
wherein:
the Xaa3-Xaa8 linkage is selected from: a Cys-Cys linkage, a Sec-Sec linkage, a cystathionine linkage, a lactam bridge, a thioether linkage, and a dicarba linkage;
the Xaa4-Xaa14 linkage is selected from: a Cys-Cys linkage, a Sec-Sec linkage, a cystathionine linkage, a lactam bridge, a thioether linkage, and a dicarba linkage;
Xaa5 is selected from: Asn, Asp, Gln, Glu, and His;
Xaa6 is selected from: Pro and hydroxyproline;
Xaa7 is selected from: Ala, Gly, Val, Leu, and Ile;
Xaa9 is selected from: Ala, Gly, Val, Leu, and Ile;
Xaa10 is selected from: His and Lys;
Xaa11 is selected from: Arg, His, and Lys;
Xaa12 is selected from: Trp and Tyr; and
Xaa13 is selected from: Cys, Met, Sec, Ser, and Thr.
5. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 1 ,
wherein:
the Xaa3-Xaa8 linkage is selected from: a Cys-Cys linkage, a Sec-Sec linkage, a cystathionine linkage, a lactam bridge, a thioether linkage, and a dicarba linkage;
the Xaa4-Xaa14 linkage is selected from: a Cys-Cys linkage, a Sec-Sec linkage, a cystathionine linkage, a lactam bridge, a thioether linkage, and a dicarba linkage;
Xaa5 is selected from: Asn and His;
Xaa6 is selected from: Pro and hydroxyproline;
Xaa7 is selected from: Ala, Gly, Val, Leu, and Ile;
Xaa9 is selected from: Ala, Gly, Val, Leu, and Ile;
Xaa10 is selected from: His and Lys;
Xaa11 is selected from: Arg, His, and Lys;
Xaa12 is selected from: Trp and Tyr; and
Xaa13 is selected from: Cys, Met, Sec, Ser, and Thr.
6. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 1 ,
wherein the Xaa3-Xaa8 linkage and the Xaa4-Xaa14 linkage are independently selected from:
(i) a Cys-Cys linkage;
(ii) a Sec-Sec linkage;
(iii) a cystathionine linkage;
(iv) a lactam bridge,
(v) a thioether linkage, and
(vi) a dicarba linkage.
7. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 6 , wherein the thioether linkage is a lanthionine linkage.
8. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 1 , wherein a N-terminus of Xaa3 is modified to comprise C 1 -C 6 acyl, C 1 -C 8 alkyl, C 6 -C 12 aralkyl, C 5 -C 10 aryl, C 4 -C 8 heteroaryl, formyl, or a lipid.
9. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 1 , wherein a C-terminus of Xaa14 is modified to comprise NH 2 , amino-acyl, amino-C 1 -C 8 alkyl, amino- C 6 -C 12 -aralkyl, amino- C 5 -C 10 aryl, amino-C 4 -C 8 heteroaryl, or O—(C 1 -C 8 alkyl).
10. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 1 , wherein a lipid is covalently attached to a cysteine, serine, lysine, threonine or tyrosine.
11. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 1 , wherein the antagonist selectively inhibits a muscle-type nicotinic acetylcholine receptor.
12. The muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 11 , wherein the IC 50 is: about 1 millimolar to about 1 picomolar, less than about 200 nM, less than about 150 nM, or less than about 100 nM.
13. A cosmetic composition comprising the muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 1 , for prevention or temporary improvement of the appearance of one or more of skin wrinkles, skin laxity, moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity, moderate to severe lateral canthal lines associated with orbicularis oculi activity, and moderate to severe forehead lines associated with frontalis muscle activity, in a subject.
14. The cosmetic composition of claim 13 , formulated for topical use.
15. A pharmaceutical composition comprising the muscle-type nicotinic acetylcholine receptor peptide antagonist of claim 1 , for: prevention or temporary improvement of the appearance of one or more of skin wrinkles, skin laxity, moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity, moderate to severe lateral canthal lines associated with orbicularis oculi activity, and moderate to severe forehead lines associated with frontalis muscle activity; treatment of overactive bladder (OAB); treatment of urinary incontinence; prophylaxis of headaches; treatment of spasticity; treatment of cervical dystonia; treatment of hypersalivation; treatment of blepharospasm associated with dystonia; or treatment of strabismus, in a subject.
16. A method for preventing or temporarily improving the appearance in a subject for prevention or temporary improvement of the appearance of one or more of skin wrinkles, skin laxity, moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity, moderate to severe lateral canthal lines associated with orbicularis oculi activity, and moderate to severe forehead lines associated with frontalis muscle activity, comprising applying an effective amount of the cosmetic composition of claim 14 to the skin of the subject.
17. A method for: preventing or temporarily improving one or more of the appearance of skin wrinkles, skin laxity, moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity, moderate to severe lateral canthal lines associated with orbicularis oculi activity, and moderate to severe forehead lines associated with frontalis muscle activity; treatment of overactive bladder (OAB); treatment of urinary incontinence; prophylaxis of headaches; treatment of spasticity; treatment of cervical dystonia; treatment of hypersalivation; treatment of blepharospasm associated with dystonia; or treatment of strabismus; in a subject, comprising administering an effective amount of the pharmaceutical composition of claim 15 to the subject.